MarketCap
Facebook
X
TelegramQuarterly report 2026-Q3
added 05-29-2026
STERIS plc Book Value 2011-2026 | STE
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value STERIS plc
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.2 B | 6.62 B | 6.32 B | 6.09 B | 6.54 B | 3.89 B | 3.39 B | 3.19 B | 3.22 B | 2.81 B | 3.04 B | 1.07 B | 1.04 B | 947 M | 823 M | 789 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.2 B | 789 M | 3.56 B |
Quarterly Book Value STERIS plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.17 B | 7.02 B | 6.97 B | 7.17 B | 7.02 B | 6.97 B | 6.62 B | 6.43 B | 6.61 B | 6.37 B | 6.32 B | 6.43 B | 6.19 B | 6.18 B | 6.09 B | 6.05 B | 5.81 B | 6.42 B | 6.54 B | 6.62 B | 6.54 B | 6.59 B | 3.89 B | 3.88 B | 3.66 B | 3.49 B | 3.42 B | 3.4 B | 3.24 B | 3.25 B | 3.19 B | - | - | - | 3.22 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.17 B | 3.19 B | 5.59 B |
Book Value of other stocks in the Medical instruments industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
243 K | - | - | $ 810 M |  USA |
 |
The Cooper Companies
COO
|
8.24 B | $ 62.02 | 2.78 % | $ 12.3 B | USA |
 |
Luminex Corporation
LMNX
|
199 M | - | - | $ 1.75 B | USA |
 |
Glaukos Corporation
GKOS
|
656 M | $ 121.69 | 7.24 % | $ 6.96 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
76.5 M | - | -9.52 % | $ 20.6 M | USA |
 |
Intuitive Surgical
ISRG
|
17.9 B | $ 418.82 | 2.83 % | $ 149 B | USA |
 |
Alcon
ALC
|
22 B | $ 66.58 | 3.67 % | $ 40.4 B |  Schweiz |
 |
ICU Medical
ICUI
|
4.05 B | $ 134.93 | 3.38 % | $ 3.32 B | USA |
 |
Repro Med Systems
KRMD
|
17 M | $ 4.14 | 5.61 % | $ 191 M | USA |
 |
iRhythm Technologies
IRTC
|
153 M | $ 107.35 | 2.67 % | $ 3.44 B | USA |
 |
LeMaitre Vascular
LMAT
|
394 M | - | - | $ 2.12 B | USA |
 |
Masimo Corporation
MASI
|
1.05 B | $ 178.9 | 0.07 % | $ 9.54 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
257 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
411 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
762 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
388 M | - | -0.05 % | $ 10.3 B | USA |
 |
Microbot Medical
MBOT
|
77.6 M | - | - | $ 89.7 M |  Israel |
 |
Ekso Bionics Holdings
EKSO
|
9.03 M | - | - | $ 28.6 M | USA |
 |
Milestone Scientific
MLSS
|
2.81 M | $ 0.43 | 11.28 % | $ 35.3 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
66.7 M | - | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
-1.71 M | $ 9.94 | 0.81 % | $ 84.3 K | USA |
 |
Envista Holdings Corporation
NVST
|
5.68 B | $ 22.87 | 2.1 % | $ 3.84 B | USA |
 |
Haemonetics Corporation
HAE
|
2.4 B | $ 69.85 | 6.03 % | $ 3.3 B | USA |
 |
Isoray
ISR
|
207 M | - | 0.03 % | $ 108 M | USA |
 |
STAAR Surgical Company
STAA
|
344 M | $ 29.86 | 5.66 % | $ 1.48 B | USA |
 |
InfuSystem Holdings
INFU
|
57.3 M | $ 9.12 | 1.0 % | $ 188 M | USA |
 |
Teleflex Incorporated
TFX
|
3.12 B | $ 132.11 | 2.76 % | $ 5.9 B | USA |
 |
Merit Medical Systems
MMSI
|
1.58 B | $ 63.04 | 3.94 % | $ 3.73 B | USA |
 |
Utah Medical Products
UTMD
|
119 M | $ 67.99 | 3.75 % | $ 220 M | USA |
 |
West Pharmaceutical Services
WST
|
3.18 B | $ 317.32 | 0.32 % | $ 22.9 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.34 B | $ 9.88 | 2.49 % | $ 1.97 B | USA |
 |
Pulse Biosciences
PLSE
|
80.7 M | $ 26.94 | 7.8 % | $ 1.82 B | USA |
 |
Retractable Technologies
RVP
|
74.4 M | $ 0.66 | 0.41 % | $ 19.8 M | USA |
 |
Pro-Dex
PDEX
|
36.6 M | $ 67.0 | 2.81 % | $ 220 M | USA |
 |
Predictive Oncology
POAI
|
47.7 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
372 M | - | - | $ 1.29 B | USA |
 |
Stereotaxis
STXS
|
18.7 M | $ 1.88 | 2.17 % | $ 171 M | USA |
 |
Baxter International
BAX
|
6.1 B | $ 19.35 | 4.31 % | $ 9.93 B | USA |
 |
ResMed
RMD
|
3.36 B | $ 194.32 | 4.2 % | $ 28.4 B | USA |
 |
AtriCure
ATRC
|
492 M | - | - | $ 1.3 B | USA |
 |
Harvard Bioscience
HBIO
|
13.7 M | - | - | $ 288 M | USA |
 |
NeuroMetrix
NURO
|
14.3 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
183 M | $ 12.03 | 7.41 % | $ 491 M | USA |
 |
Becton, Dickinson and Company
BDX
|
55.3 B | $ 149.56 | 2.73 % | $ 43 B | USA |
 |
Nephros
NEPH
|
10.2 M | $ 3.59 | -1.37 % | $ 38.1 M | USA |
 |
OraSure Technologies
OSUR
|
341 M | $ 4.17 | 5.57 % | $ 306 M | USA |
 |
Repligen Corporation
RGEN
|
2.11 B | $ 126.55 | 3.96 % | $ 7.12 M | USA |